A Preview Of INmune Bio's Earnings
Portfolio Pulse from Benzinga Insights
INmune Bio (NASDAQ:INMB) is scheduled to release its quarterly earnings report on March 28, 2024, with analysts expecting an EPS of $-0.44. The company's past earnings performance shows a mixed record of beating and missing EPS estimates, affecting its stock price. Shares of INmune Bio have seen a significant increase over the last year, trading at $11.88 as of March 26, with a 99.42% rise over the 52-week period. Investors are looking forward to not only the earnings results but also the company's guidance for future growth.
March 27, 2024 | 6:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
INmune Bio is anticipated to announce its quarterly earnings with an expected EPS of $-0.44. The company's stock has significantly appreciated over the past year, indicating strong investor confidence.
The expected EPS of $-0.44 sets a cautious tone, but the historical stock performance and the 99.42% increase over the past year suggest strong investor confidence. The actual impact will depend on whether the earnings beat or miss expectations and the future guidance provided by the company.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100